California Stem Cell Finances: A Tale of Delay and 'Helpful' Oversight

Involved are findings from a $230,000 performance audit of CIRM

Apr 25, 2022

∙ Paid

California’s multibillion-dollar, cell and gene therapy program has a special spot in the pantheon of the hundreds of government departments in the Golden State.

It is immune from the normal oversight of the governor and state lawmakers. Its cash -- now set at $5.5 billion over the next decade -- flows freely and directly to the stem cell agency with no…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.